Subject Index

Abdominal incisions, 251
Ablation, ovarian, premenopausal women and, 340
Activin-A, 79
Adjuvant Chemoendocrine (ACE) study, 347
Adjuvant Tamoxifen Treatment–Offer More? (aTTom), 346
Adjuvant therapy
  EBCTCG overview of, 339
  endocrine aspects of, 313
  endocrine factors in outcome of, 330
Adr^{200}MCF-7 cell line, *GSTπ* gene and, 183
Adriamycin
  MPTC-63 pretreatment and, 161
  resistance to, 183
Aesthetic results, double-lumen prostheses and, 252
Alendronate, 368
Alkylating agents, resistance to, 303
Alopecia, 375
Amenorrhea, drug-induced, 331
American Radiological Society, 153
Aminoglutethimide, 357
Amsacrine, drug resistance and, 301
Angiogenesis
  prognostic implications of, 75
  regulation of, 78
  tumor growth and, 64
Antibodies, engineered, 413
Antibody directed enzyme pro-drug therapy (ADEPT), 81
Anticoagulant activity, pentoxan polysulfate doses having, 66
Antiestrogen drugs, 177
Antimetabolites, resistance to, 304
Assay systems, cell kinetics and, 282
Autologous bone marrow transplantation (ABMT)
  dose intensity and, 285
  high-dose chemotherapy and, 379
Autologous tissues, reconstruction using, 246
Axillary involvement, 262
Axillary lymph node status, 170

Biological markers, clinical protocol design and, 271
Bisphosphonates, 367
Bone marrow support, high-dose chemotherapy without, 389
Bone metastases, clodronate in, 367
Brachytherapy, 264
Breast cancer
  adjuvant therapy of, 339
  advanced
    clodronate in, 367
    GSTπ gene in, 182
    mastectomy not used in treatment of, 264
    somatuline and, 362
  angiogenesis in, 71
  antineoplastic drug resistance and, 289
  c-erb-B2 oncoprotein and, 167
  cell kinetics in, 186
  chromosome 17p13.3 and, 120
  conservative surgery in, 212
  critical steps in, 1
  early
    ACE study of, 347
    chemohormonal adjuvant therapy of, 318
    endocrine factors in, 330
  endocrine adjuvant therapy of, 318
  endocrine aspects of adjuvant treatment of, 313
  frequent mutations in, 21
  growth factors and, 85
  high-intensity chemotherapy in, 378
  histologic type of, 114
  iron metabolism and, 159
  kinetic concepts and, 48
  large, 265
  lonidamine in, 349
  marker expression and differentiation in, 143
  metastatic, 349
    Taxol and G-CSF in, 398
    Taxol cardiotoxicity in, 403
  neoadjuvant chemotherapy and, 193
  NM23-H1 and onset of, 139
  positron emission tomography of glucose metabolism in, 423
  progesterone receptor determination and, 150
  radioimmunoconjugates and, 406
  reconstructive surgery in, 219
  second-line hormone therapy in, 357
  S-phase fraction and, 193
  stimulation of, 418
  thermographic prognostic procedure in, 153
  tumor-associated antigens and, 31
Breast Cancer Detection and Demonstration Projects (BCDDP), 153
Breast conserving strategies (BCS) (*see* Conservation, breast)

Breast lobe, 212
Breast reconstruction (BR) (*see* Reconstruction, breast)
Breast tumor cell invasion, role of CSF-alpha in, 132
5-Bromo-2-deoxyuridine, DNA content versus incorporation of, 175
Buthionine sulfoximine (BSO), drug resistance and, 302

C-*erb*-B2 gene
  IL-8 responsiveness and, 127
  overexpression of, 36
c-*erb*-B2 oncogene, progesterone receptor and, 183
c-erb-B2 oncoprotein, receptor status and proliferating activity and, 167
c-*erb*-B2 protooncogene, 103
c-Ha-*ras* gene, loss of heterozygosity of, 10
c-Ha-*ras* protooncogene, 103
c-*myc* oncogene, 94
C_{18} reversed-phase HPLC, 206
Calcium, mechanism of immortalization and, 6
cAMP-dependent protein kinase, 102
Cancer and Leukemia Group B (CALBG), 51
  dose intensity and, 284
Carboplatin, 384
Cardiotoxicity, Taxol, 403
Cathepsin, prognostic potential of, 273
Cathepsin-D, characterization of, 89
CD31 (anti-PECAM, platelet/endothelial cell adhesion molecule), 72
Cell kill, dose and, 279
Cell kinetics
  assay systems and, 282
  clinical relevance of, 186
  method to study, 175
  prognostic information provided by, 272
Cell phenotype, antigen expression and, 32
Cell proliferation, growth rate of breast primary cultures and, 2
Cell proliferation kinetics
  ^{125}IUdR incorporation based on, 205
  radioiodinated IUdR and, 207
Chemical carcinogens, molecular changes induced by, 9
Chemohormonal adjuvant therapy, 318
Chemotherapy
  combination, 49
  features of, 280
  high-intensity
    with hematopoietic support, 378
    without bone marrow support, 389
  multiple cycles of, 56
  neoadjuvant, 193
    without mastectomy, 264
  positron emission tomography scan in, 427
  premenopausal women and, 340
  sequential, 56
  TLI values and, 190
  tumor shrinkage and, 48
Chromosomal abnormalities, 93
Chromosome 17P13.3, 120
Chromosome 17q, definition of a deletion map on, 136
cis-platinum-transferrin complex (MPTC-63), 160
Clearance curves, 205
Clinical protocols, biological markers for designing, 271
Clodronate, 367
Clonogenicity, 96
Collagen-induced morphogenesis, 36
Colony-stimulating factors, severe hematologic toxicity reversed by, 286
Combination chemotherapy, 49
COMMA D cell line, 24
Conservation, breast
  evolution of treatment towards, 193
  long-term results of, 259
  strategies, 227
  surgery and therapy for, 260
  surgery in, 212
Cost benefit analysis, 315
Cyclophosphamide
  high-dose, 384
  lonidamine plus epirubicin and, 350
  resistance to, 303
Cyclophosphamide, epidoxorubicin, 5-fluorouracil (CEF)
  DES and, 419
  GM-CSF and, 393
Cyclophosphamide, methotrexate, 5-fluorouracil (CMF), 50
  dose intensity of, 285
Cytoreduction, 54
Cytotoxic agents, drug resistance and, 291
Cytotoxicity, drug, free radical-mediated, 301

Diethilstibestrol (DES), 418
Differentiation, 144
  TLI values and, 188
Dihydrofolate reductase (DHFR), MTX binding to, 304
3-(4,5-Dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide, 127
Dose escalation, 379
Dose intensity, 279
  original concept of, 390
Drug-induced amenorrhea (DIA), 331
Dual-parameter flow cytometry, 177
Ductal carcinomas, *in situ*, 229
Duration, high-dose chemotherapy and, 56

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), 339
Eastern Cooperative Oncology Group (ECOG), dose intensity and, 285
Emotional recovery, 374
Emotional trauma, immediate reconstruction prevents, 223
Endocrine adjuvant therapy, 318
Endocrine approach, 314
Endocrine factors, adjuvant therapy and, 330
Enzyme, drug resistance and, 292
Epidermal growth factor receptor
  clinical significance of, 91
  high expression of, 57–58
Epidermal growth factor receptor expression, poor prognosis and, 34
Epirubicin, lonidamine and cyclophosphamide and, 350
erb-B2 gene, transformation of HBEC and, 11
Estrogen receptor (ER)
  breast tumor proliferating cells and, 144
  progesterone receptor inverse relation to, 188
  prognostic information provided by, 272
  tamoxifen and, 334
Estrogen receptor status, adjuvant tamoxifen and, 315
Estrogen-regulated proteins, 88
External beam therapy, 264

Fatigue, 375
Ferritin, serum, elevation of, 159
Fibroblast growth factor gene family, 22
Fibroblasts, rat embryo, 112
Fine-needle cytology, 194
Flow cytometry, cell cycle changes and, 175
^{18}F-Fluoro-2-deoxy-D-glucose (FDG), 424
5-Fluorouracil (5-FU), drug resistance and, 306
Focal hot spots, thermography and, 154
Free radical-mediated drug cytotoxicity, 301
Frequent mutations in breast cancer, 21

Gamma interferon, 412
Gene expression, *NM23-H1* loss of heterozygosity and, 138
Gene products, drug resistance and, 292
Genotypic alterations, antigens showing, 34
Glucose metabolism, 423
Glutathione peroxidase (GSHPx), drug resistance and, 302
Glutathione S-transferase (GST), drug resistance and, 298
Gluteus area, 232
Glycosylation of polymorphic epithelial mucin, 39
Goldie-Coldman hypothesis, 50
Gompertzian model
  cell kill and, 378
  illustration of, 51
Granulocyte colony-stimulating factor (G-CSF)
  dose-limiting toxicity and, 375
  high-dose chemotherapy and, 383
  Taxol and, 398
Granulocyte-macrophage colony-stimulating factor (GM-CSF), high-dose chemotherapy and, 383, 389
GROCTA trials, 318
Growth factors, clinical implications of, 85
Growth rate of breast primary cultures, 2
Growth rate of tumors
  Gompertzian hypothesis and, 53
  metabolic heat pattern and, 155
  thermography prediction of, 153
GSTπ gene, 182

HC11 rodent mammary epithelial cells, 108
Hematopoietic support technology, 383
Heparin-binding growth factor, pentosan polysulfate and, 63
HER2/neu/c-*erb*-B2 gene, 94
Histologic type of invasive breast carcinoma, 114
Hormonal manipulations, 418
Hormonal therapy, TLI values and, 189
Host antimonoclonal antibody (HAMA) response, 411
Huggins carcinogen-induced rat mammary carcinoma, 65
Human breast epithelial cells (HBEC), 3
  cAMP-dependent protein kinase and, 102
  cytokine production and response and, 126
  overexpression of *c-erb*-B2 gene and, 36
Hypofractionated protocol (IHF), 265

Immortalization
  mechanisms of, 5
  wild-type *p53* activity and, 112
Immunocytochemistry
  c-erb-B2 oncoprotein and, 167
  marker expression studied by, 144
  p53 protein expression evaluated by, 116
Immunoscintigraphy, 429
Immunotherapy with polymorphic epithelial mucin-based immunogens, 40
Implants
  complications with use of, 247
  permanent expandable, 247
Inflatable devises, 252
Insulin-like growth factor (IGF)-1, somatuline effect on, 364
Insulin-like growth factor-1-receptor, human breast cancer and, 91
int-2/bcl-1 gene, 95
int-2 gene, IL-6 stimulation and, 127

int-3 locus, activation of, 22
Interleukin-6, 127
Interleukin-8, 127
Intracytoplasmic lumina, 161
Intraductal permeation, 212
Intranuclear incorporation, 207
Intratumor injection, 205
Inverse rule of dose and cell kill, 279
5-[^{125}I]Iodo-2′-deoxyuridine, 127
  tumor targeting potential of, 204
Iron metabolism, breast carcinoma and the role of, 159
Isodose, 265

JC70 monoclonal antibody, 72

Kaplan-Meier method, 221
Keratin-positive cells, 33
Ki-67
  immunocytochemical determination of, 156
  proliferating activity evaluated by, 167
Kinetic concepts, 48

Latissimus dorsi musculocutaneous flap
  delayed reconstruction and, 231
  impact of, 220
Leucovorin (N^5-formyl tetrahydrofolate), 305
Liposomes, MAb-labeled, 429
Lobectomy, 212
Local-regional administration, efficient incorporation of IUdR by, 205
Local-regional failure, 268
  S-phase influence on, 194
Local-regional treatment, 271
Log-kill model, 49
Lonidamine, 349
Loss of heterozygosity
  loci on chromosomes and, 121
  mutations in primary breast tumors and, 25
  NM23-H1 cell a target of, 136
Lung metastases, 160
Luteinizing hormone-releasing hormone (LHRH) analogs, 333
Lymph node metastases, 425
Lymph node status, p185 and, 171

Maintenance treatment, lonidamine as, 351
Mammary gland development, 2
Marked mononuclear cell reaction, 131
Marker expression, cell differentiation and, 145
Mastectomy
  Halsted, QUART technique and, 213
  Halsted radical, 220
  locally advanced breast cancer without, 264
  Madden modified radical, 219
  modified radical (MRM), 229
    immediate reconstruction following, 247
  Patey modified radical, 219
  radical, immediate reconstruction with prosthesis following, 254
  reconstruction after, 219
  subcutaneous, immediate reconstruction following, 247
MCF-10 cells, immortalization of, 5
MCF-10A cells, 102
  cytokine production and response and, 126
mdr genes, drug resistance and, 294
Megatrials, need for, 345
Menopausal symptoms, 375
Metabolite, 206
Metastatic breast cancer (MBC), lonidamine and, 349
Methotrexate (MTX), drug resistance and, 304
Microautoradiography, 206
Milan CMF trials, 333
  dose intensity and, 285
  Trial I, 213
  Trial II, 215
  Trial III, 216
Modulators, growth factor, 64
Monoclonal antibody (MAb)
  human breast cancer markers and, 144
  radiolabeled, 407
Monoclonal antibody B72.3, TAG-72 and, 408
Monoclonal antibody CC49, TAG-72 and, 407
Monoclonal antibody-labeled liposomes, 429
Monocyte colony-stimulating factor, 132
Mouse mammary tumor virus, 21
MTSV1-7 cell line, 36
MUC-1 gene, 39
Multiple cycles of chemotherapy, 56
Multiple-cycle high-dose chemotherapy, 384
Multiple-modality therapy, premenopausal women and, 342
Myelosuppression, 410

Naples GUN-1 adjuvant trial, 334
National Surgical Adjuvant Breast Project (NSABP), 333
Nausea and vomiting, 375
Needles, metal guide, 264
Neoadjuvant chemotherapy, S-phase prognostic value and, 193
Neovascularization, metastatic spread of breast cancer and, 64
Neutropenia, 375
Nipple-areolar complex reconstruction, 237
NM23-H1 cell, hypothetical suppressor function of, 136
NM23-H1 gene, LOH effect on, 25
Nodal status, thermographic findings and, 155
Node metastatic diffusion, 151
Node-negative tumors, 271

Nodes, multiple involved, chemotamoxifen treatment and, 325
Nolvadex Adjuvant Trial Organization (NATO), 335
Nonsurgical approaches, S-phase fraction and, 197
Notch gene family, 23

Oncogene products, 167
Oncogenes, cytokine production and response and, 126

p53 gene
  chromosome 17p13.3 and, 120
  germline mutations of, 25
  mutations and overexpression of, 117
  prognostic potential of, 274
  progression vs. initiation and, 34
  transformation of HBEC and, 12
  wild-type, 108
p185 oncoprotein, 167–168
Pain relief, 370
Partial thromboplastin time, 66
Patient
  breast reconstruction decision of, 233
  intelligent recommendations to, 315
  participation of, 229
  quality of life of, 372
Pentosan polysulfate, heparin-binding growth factor blockade with, 63
Percutaneous, ultrasound-guided injection, intratumoral administration by, 205
Permanent expandable implants (PEI) (*see* Implants)
Pharmacokinetics, IUdR injection and, 209
Plasminogen activators, 89
Platelet-derived endothelial cell growth factor, 79
Ploidy, prognostic information provided by, 272
Point mutation, *p53* gene, 124
Polychemotherapy
  Gompertzian hypothesis and, 53
  tamoxifen and, 316
Polymerase chain reaction, 115
Polymorphic epithelial mucin, aberrant glycosylation of, 39
Polyspecific artificial carriers, 429
Positron emission tomography (PET) of glucose metabolism, 423
Postmenopausal women, adjuvant chemotherapy in, 315
Productive fibrosis, 148
Progesterone receptor
  arrest of DNA synthesis and, 144
  c-*erb*-B2 oncogene and, 183
  epithelial expression of, 148
  estrogen receptor inverse relation to, 188
  tamoxifen and, 334
Prognosis, S-phase fraction and, 193
Prognostic factors, 86
  biological, 272
  clinical use of, 274
  neoadjuvant chemotherapy and brachytherapy and, 268
Prognostic implications of angiogenesis, 75
Prognostic indicator, thermography as, 153
Prolactin receptor, tamoxifen and, 334
Proliferating activity, c-erb-B2 oncoprotein and, 167
Proliferating cell nuclear antigen (PCNA), 175
Proline, glutamic acid, serine, threonine (PEST) sequence, 23
Prosthesis
  double-lumen, 247
  external, 223
    getting accustomed to, 258
  radical mastectomy and immediate reconstruction with, 254
  silicone, 236
  submuscular implantation of, 220
  tissue expander versus, 229
Protooncogenes, increased expression of, 33
pS2 protein, 88
pTHH59, 139
Ptosis, creation of, 252
pYNZ22, 139

Quadrantectomy, 212
Quality of life, 372
QUART technique, 213

Radial breast resection, 212
Radioiodouracil, 207
Radioisotope-charged MAb-labeled liposomes, 430
Radiolabeled monoclonal antibody (MAb), 407
Randomized trials
  dose assessment and, 391
  usefulness of, 316
ras oncogene, transformation of HBEC and, 9
Rb gene, transformation of HBEC and, 12
Reconstruction
  breast
    advantages of immediate, 235
    alternatives in, 246
    complications of, 235
    delayed, 231
    immediate, 229
    impact of, 219
    mastectomy and, 228
    with prosthesis, 254
  nipple-areolar complex, 237
    patients who refuse, 256

Recurrence
local, reconstruction and, 225
mastectomy done for, 266
tamoxifen versus chemotherapy and, 320
Relapse, predictive value for site of, 96
Repair mechanisms, altered, 291
Resistance
alkylating agent, 303
antimetabolite, 304
cyclophosphamide, 303
drug
antineoplastic, 289
high-dose chemotherapy and, 382
mechanisms of, 291
random mutations and, 50
drug-metabolizing enzymes and, 297
multidrug, 292
P-glycoprotein-mediated, 292
topoisomerases and, 295
Response to treatment
lonidamine and, 352
low S-phase fraction patients and, 197–200
none versus partial and complete, 283
Taxol and, 400

S-phase fraction
mitotoxicity of chemotherapy and, 57
prognostic value of, 193
S-phase index, chromosome location and, 121
Scavenging enzymes catalase, drug resistance and, 302
Second-line hormone therapy, tamoxifen continuation during, 357
Selective medical treatment, 191
Sequential chemotherapy, 56
Sexual concerns, 375
Single-strand conformation polymorphism analysis, 114
Somatostatin receptors, 92
Somatuline, tamoxifen and, 362
Split-course interstitial brachytherapy with a source shift (SCISS), 265
Statin, mechanism of tamoxifen and, 175
Stem cell hierarchy hypothesis, 143
Steroid receptor, 87
c-erb-B2 oncoprotein and, 167
prognostic information provided by, 272
tamoxifen and, 334
Stimulation of human breast cancer *in vivo*, 418
Submuscular pocket
anatomical borders of, 255
filling ports and, 247
immediate breast reconstruction and, 229
Surgery
abdominal, women smokers with previous, 237
conservative, 212
reconstructive, impact of, 219
Survival
adjuvant systemic therapy and, 313
adjuvant therapy improves, 331
disease-free, 282
neoadjuvant chemotherapy and brachytherapy and, 268
ovarian suppression and, 344
quality of life and, 373
reconstruction and, 219
S-phase fraction influence and, 194
tamoxifen versus chemotherapy and, 320
TLI values and, 188
Syngeneic model system, 40

TAG-72, MAb CC49 targets, 407
Tamoxifen, 57
aTTom Study and, 346
cell cycle kinetic effects of, 174
chemotherapy versus, 319
choice of, 315
estrogen receptor-negative tumors and, 334
GSTπ gene expression and response to, 182
premenopausal women and, 341
second-line hormone therapy and, 357
somatuline and, 362
Tandem repeats domain, 39
Targeting
MAb-labeled liposomes in, 429
tumor, radioiodinated IUdR and, 207
vascular, 80
Targets, tumor-associated antigens as, 35
TART, 215
Taxol
cardiotoxicity of, 403
G-CSF and, 398
T47D cells, TNF-alpha and, 127
Therapeutic potentials, radiolabeled IUdR and, 207
Therapy, resistance to, 49
Thermography, breast, 153
^{3}H-Thymidine labeling index (TLI)
cell kinetics assessed by, 170
cell kinetics evaluated as, 186
prognostic relevance of, 273
Tissue expander
Baker, 232
prosthesis versus, 229
Radovan, 232, 246
Topoisomerases, 295
Toxicity
dose intensity and, 286
hematopoietic support technologies and, 384
lonidamine plus epirubicin and cyclophosphamide, 354
pentoxan polysulfate, 67
Transcription factor, 112

Transferrin, iron-bound, 159
Transforming growth factor (TGF)-alpha, cultures treated with, 127
Transforming growth factor-alpha gene, 103
Transforming growth factor-beta, tamoxifen and, 316
Transforming growth factor-beta-1, angiogenic response to, 78
Transgenic mice, human *MUC-1* gene and, 41
Transverse rectus abdominis myocutaneous (TRAM) flap
  complications with use of, 247
  delayed reconstruction and, 231
  impact of, 220
Tumor aggressiveness, *NM23-H1* loss of heterozygosity and, 139
Tumor-associated antigens (TAA), 31, 407
Tumor/blood ratio, 207
Tumor heterogeneity, outcome influenced by, 280
Tumor necrosis factor, 413
Tumor/nontumor radioactivity incorporation ratios, 207
Tumors, large primary, chemotamoxifen treatment for, 325

Ultrastructural study, iron metabolism, 159
Urinary excretion of radioactivity, 207
Urokinase, 132

Vascular invasion, 76
Vascular targeting, 80
Vector tubes, plastic, 264
Vinblastine, doxorubicin, thiotepa, fluoxymesterone (VATH), 51

Wild-type *p53* gene, 108
World Overview of Adjuvant Systemic Therapy for Early Breast Cancer, 313
World-Wide Overview, 51

Index of Contributors

Addamo, G. F., 389–397
Adelstein, S. J., 204–211
Aldrighetti, D., 318–329
Alvarado, M. E., 1–20
Amadori, D., 186–192, 418–422
Amaducci, L., 186–192
Amalric, R., 259–263
Amoroso, D., 318–329
Arbuck, S., 398–402
Ardizzoni, A., 389–397
Augustine, S., 406–417
Ayme, Y., 259–263

Badellino, F., 219–226
Baillet, F., 264–270
Baldassarre, G., 102–107
Baldini, E., 349–356, 418–422
Baldini, F., 403–405
Ballare, C., 143–147
Baranowska-Kortylewicz, J., 204–211
Barone, C., 349–356
Basolo, F., 126–130
Baum, M., 313–317
Beghé, F., 367–371
Bellettieri, R. J., 372–377
Berdichevsky, F., 31–47
Berkery, R., 398–402
Bernardi, A., 120–125
Berns, P. M. J. J., 85–101
Berrino, P., 246–253
Bertelli, G., 357–361
Beuvon, F., 131–135
Beviglia, E., 254–258
Bevilacqua, G., 136–142, 204–211
Biadi, O., 403–405
Bianco, A. R., 102–107, 330–338
Bianco, C., 102–107
Bicknell, R., 71–84
Bistocchi, M., 114–119
Boccardo, F., 318–329, 362–366
Bonacci, R., 148–152
Bonichon, F., 182–185
Bontenbal, M., 85–101
Bravo, A. I., 143–147
Brema, F., 418–422
Burchell, J., 31–47
Buttitta, F., 114–119

Calaf, G., 1–20
Caligo, M. A., 136–142
Callahan, R., 21–30, 108–113, 114–119, 120–125
Calvo, S., 126–130
Camoriano, A., 349–356
Campani, D., 114–119, 148–152, 167–173
Canavese, G., 219–226
Canetta, R., 398–402
Cannata, D., 362–366
Canobbio, L., 362–366
Cappa, A. P. M., 120–125
Cappellini, M., 318–329
Carlomagno, C., 330–338
Castagnetta, L., 318–329
Catturich, A., 219–226
Cecchetti, D., 114–119, 167–173
Chauveinc, L., 264–270
Ciardiello, F., 102–107
Clarke, M., 339–348
Coindre, J. M., 182–185
Colcher, D., 406–417
Collecchi, P., 204–211
Colletta, A., 313–317
Collins, R., 339–348
Conaldi, P. G., 126–130
Conte, P. F., 349–356, 403–405, 418–422
Contu, A., 349–356
Cossu, F., 429–435
Costa, A., 212–218

Cowan, K. H., 182–185, 289–312
Cropp, C., 21–30
Crown, J. P. A., 378–388, 398–402
Currie, V., 398–402

Dalrymple, G., 406–417
Danova, M., 174–181
DeLap, R., 63–70
De Laurentiis, M., 330–338
Del Mastro, L., 330–338, 389–397
de Luca, F., 167–173
Demontis, B., 227–245
de Negri, F., 148–152
De Placido, S., 330–338
d'Errico, F., 254–258
De Sanctis, C., 318–329
DeVita, V. J., Jr., 279–288
Diella, F., 21–30, 114–119, 120–125
Di Luca, L., 204–211
Di Martino, L., 227–245
Di Sacco, S., 204–211
Dorion-Bonnet, F., 182–185
D'Souza, B., 31–47
Durand, J. C., 193–203
Durand, M., 182–185

Elliott, M. C., 159–166
Elliott, R. L., 153–158, 159–166
Estienne, M., 219–226
Estrada, S., 1–20

Fabbri, R., 148–152
Falcone, V., 126–130
Farris, A., 318–329
Fennelly, D., 378–388
Ferrario, E., 254–258
Fierabracci, P., 148–152
Fiore, L., 126–130
Fisherman, J., 398–402
Foekens, J. A., 85–101
Fontanini, G., 167–173
Fourquet, A., 193–203
Franchelli, S., 246–253
Francis, P., 378–388

Gallahan, D., 21–30
Gallo, C., 330–338
Gallo, L., 318–329
Gallotti, P., 418–422
Garau, A., 227–245
Gardin, G., 349–356, 418–422
Garrone, O., 389–397
Gentilini, P., 418–422
Gherarducci, G., 403–405
Ghimenti, C., 136–142
Giani, C., 148–152
Giannessi, P. G., 349–356, 403–405, 418–422
Gibelli, N., 174–181
Gigliotti, A., 148–152
Gilewski, T. A., 378–388, 398–402
Giordano, M., 174–181
Giuliani, L., 204–211
Gray, R., 339–348
Gualde, N., 182–185

Hakes, T. B., 398–402
Hamilton, N., 378–388
Harris, A. L., 71–84
Harrison, K., 406–417
Head, J. F., 153–158, 159–166
Heelan, R., 398–402
Holdeman, K., 406–417
Horak, E. R., 71–84
Hortobagyi, G. N., 423–428
Housset, M., 264–270
Hudis, C. A., 378–388, 398–402
Hynes, N. E. 108–113

Iacobelli, S., 318–329
Ianniello, G., 349–356

Joshi, S., 406–417

Kassis, A. I., 204–211
Kim, E. E., 423–428
Klijn, J. G. M., 85–101
Kritz, A., 378–388

Kurtz, J. M., 259–263
Kyprianou, N., 31–47

Lanfranco, C., 418–422
Lauria, R., 330–338
Lebwohl, D. E., 398–402
Leichner, P., 406–417
Leone, M. S., 246–253
Licheri, S., 227–245
Lidereau, R., 21–30, 131–135
Linder, J., 406–417
Lippman, M., 63–70
Liscia, D. S., 21–30, 120–125
Lundi, N., 186–192
Luzzani, M., 367–371

Magdelénat, H., 193–203
Magni, E., 186–192
Mammoli, C., 148–152
Mangiorotti, R., 174–181
Marchetti, A., 114–119
Mariani, M., 403–405
Mariani, G., 204–211
Mariani, G. L., 389–397
Marinelli, A., 330–338
Martini, L., 167–173
Mauriac, L., 182–185
Mazzini, G., 174–181
Mellis, G., 429–435
Mengozzi, G., 403–405
Merlini, L., 349–356
Merlo, G. R., 21–30, 108–113, 120–125
Mesiti, M., 318–329
Meszaros, P., 219–226
Meucci, G., 204–211
Miglietta, L., 362–366
Monzeglio, C., 418–422
Mordoh, J., 143–147
Morgagni, S., 186–192
Morrow, C. S., 289–312
Mortganti, M., 126–130
Moscow, J. A., 182–185
Mosseri, V., 131–135, 193–203
Muggianu, M., 219–226
Murenu, G., 227–245
Mustacchi, G., 318–329

Nanni, O., 186–192
Nascimben, O., 349–356
Naso, C., 349–356, 418–422
Nenci, I., 318–329
Nieweg, O. E., 423–428
Norton, L., 48–62, 378–388, 398–402
Nuti, M., 143–147

Pacini, P., 318–329
Palud, C., 131–135
Parker, B., 63–70
Pastorino, G., 418–422
Pastorino, S., 219–226
Pavanato, G., 418–422
Pellegrini, S., 114–119
Pellicciari, C., 174–181
Penucci, M. C., 389–397
Pepe, S., 102–107
Perrone, F., 330–338
Peto, R., 339–348
Piffanelli, A., 318–329
Pinchera, A., 148–152
Pouillart, P., 131–135, 193–203
Pronzato, P., 349–356, 357–361, 418–422

Quadri, S., 406–417
Queirolo, P., 389–397
Quénel, N., 182–185
Quinlivan, S., 398–402

Reed, E., 406–417
Reichman, B. S., 398–402
Remvikos, Y., 193–203
Riccardi, A., 174–181
Rombi, G., 429–435
Rosso, M., 349–356, 357–361
Rosso, R., 349–356, 389–397, 418–422
Rozec, C., 264–270
Rubagotti, A., 318–329, 418–422
Ruggiero, A., 102–107
Russo, I. H., 1–20
Russo, J., 1–20

Salvadori, P. A., 204–211
Santi, P. L., 246–253
Sarnelli, R., 167–173
Schiaffi, J., 143–147
Schieppati, G., 318–329
Schneider, J., 378–388
Scholl, S. M., 131–135
Seidman, A. D., 398–402
Selvam, M. P., 102–107
Serra, C., 126–130
Sertoli, M. R., 389–397
Silvestrini, R., 271–278
Silvestro, S., 389–397
Singletary, S. E., 423–428
Sismondi, P., 318–329
Smith, G., 21–30
Sohi, N., 1–20
Spitalier, J. M., 259–263
Squartini, F., 114–119, 126–130, 148–152, 167–173
Steakley, C., 63–70
Strata, G., 403–405
Stuart, N., 71–84
Sturba, F., 349–356
Surbone, A., 48–62, 279–288, 398–402, 403–405
Swain, S., 63–70

Tahin, Q., 1–20
Tang, R., 131–135
Taverna, D., 108–113
Taylor-Papadimitriou, J., 31–37
Tempero, M., 406–417
Testore, F., 418–422
Tomei, T., 219–226
Toniolo, A., 126–130
Toomasi, F., 398–402
Tortora, G., 102–107
Traina, A., 318–329
Turchi, V., 143–147

Ucla, L., 264–270

Vahdat, L., 378–388
Van den Abbeele, A. D., 204–211
Vecchio, C., 219–226
Venesio, T., 108–113, 120–125
Venturini, M., 389–397
Veronesi, U., 212–218
Viacava, P., 204–211
Villa, E., 318–329
Volpi, A., 186–192

Wafflart, J., 182–185
Wang, E., 174–181
Wang, F., 153–158, 159–166
Wasserheit, C., 378–388
Weill, M., 264–270
Wellstein, A., 63–70
Wong, W.-H., 423–428

Yao, T. J., 398–402
Yomha, R., 143–147

Zajdela, A., 193–203
Zhang, P. L., 1–20
Zibera, C., 174–181